There's more to the rheumatoid arthritis field than the Humira biosimilar race, Ablynx' Edwin Moses tells TPL

The race to come up with a biosimilar version of the rheumatoid arthritis treatment Humira (adalimumab) – the world’s top-selling drug – is well and truly on.

For a group of RA patients for whom Humira is not suitable, however, of much more concern is the prospect of another treatment becoming available.

Belgian drugmaker Ablynx (Euronext Brussels: ABLX) Ablynx is focusing its efforts on that group of patients. The company has just presented positive top-line data in a Phase IIb study of its anti-IL-6R Nanobody, vobarilizumab, in patients who have moderately to severely active rheumatoid arthritis (RA) and are intolerant to methotrexate (MTX) or for whom continued MTX treatment is inappropriate.